Due to the specific binding of Metuximab to the tumor surface antigen, Licartin might theoretically bind more to HAbl8G/CD147 over-expressed on the hepatic carcinoma cells, while the binding rate of normal liver tissue to Licartin is low, thus reducing the influence on normal hepatocytes (26). Here, BSG is linked to hepatocellular carcinoma.